Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Total Assets of $4.97 billion for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $4.97B | +17.1% |
| 2024 | $4.24B | +10.7% |
| 2023 | $3.83B | +8.0% |
| 2022 | $3.55B | -2.7% |
| 2021 | $3.64B | +6.9% |
| 2020 | $3.41B | +42.2% |
| 2019 | $2.40B | +52.1% |
| 2018 | $1.57B | -21.1% |
| 2017 | $1.99B | +58.0% |
| 2016 | $1.26B | -8.9% |
| 2015 | $1.39B | +28.4% |
| 2014 | $1.08B | +156.7% |
| 2013 | $420.53M | +46.3% |
| 2012 | $287.52M | +2.0% |
| 2011 | $281.92M | -28.3% |
| 2010 | $393.26M | -18.3% |
| 2009 | $481.38M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.85B | +15.4% | +6.3% |
| June 30, 2025 | $4.57B | +13.9% | +8.4% |
| March 31, 2025 | $4.21B | +10.2% | -0.6% |
| December 31, 2024 | $4.24B | +10.7% | +0.8% |
| September 30, 2024 | $4.21B | +9.5% | +4.9% |
| June 30, 2024 | $4.01B | +17.8% | +4.8% |
| March 31, 2024 | $3.82B | +12.7% | -0.1% |
| December 31, 2023 | $3.83B | +8.0% | -0.2% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.1% in Total Assets compared to the prior fiscal year.
- Over the 2009–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s total assets has grown by 931.7% (from $481.38 million to $4.97 billion).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: